Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?

Prostate cancer is a slow-growing disease, but not always. A highly rare and lethal form of the disease shows survival rates of less than a year. It is called squamous cell prostate carcinoma. In this issue of JEM, Hermanova et al. (https://doi.org/10.1084/jem.20191787) provide new findings in mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Grinu, Trotman, Lloyd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971130/
https://www.ncbi.nlm.nih.gov/pubmed/32236496
http://dx.doi.org/10.1084/jem.20200087
_version_ 1783666558184194048
author Mathew, Grinu
Trotman, Lloyd C.
author_facet Mathew, Grinu
Trotman, Lloyd C.
author_sort Mathew, Grinu
collection PubMed
description Prostate cancer is a slow-growing disease, but not always. A highly rare and lethal form of the disease shows survival rates of less than a year. It is called squamous cell prostate carcinoma. In this issue of JEM, Hermanova et al. (https://doi.org/10.1084/jem.20191787) provide new findings in mouse demonstrating a strong genetic handle on both the reasons behind the rarity and the aggressiveness.
format Online
Article
Text
id pubmed-7971130
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-79711302021-03-26 Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer? Mathew, Grinu Trotman, Lloyd C. J Exp Med Insights Prostate cancer is a slow-growing disease, but not always. A highly rare and lethal form of the disease shows survival rates of less than a year. It is called squamous cell prostate carcinoma. In this issue of JEM, Hermanova et al. (https://doi.org/10.1084/jem.20191787) provide new findings in mouse demonstrating a strong genetic handle on both the reasons behind the rarity and the aggressiveness. Rockefeller University Press 2020-04-01 /pmc/articles/PMC7971130/ /pubmed/32236496 http://dx.doi.org/10.1084/jem.20200087 Text en © 2020 Mathew and Trotman http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Mathew, Grinu
Trotman, Lloyd C.
Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title_full Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title_fullStr Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title_full_unstemmed Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title_short Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
title_sort competence against insufficiency: why are men mostly safe from a rare and deadly prostate cancer?
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971130/
https://www.ncbi.nlm.nih.gov/pubmed/32236496
http://dx.doi.org/10.1084/jem.20200087
work_keys_str_mv AT mathewgrinu competenceagainstinsufficiencywhyaremenmostlysafefromarareanddeadlyprostatecancer
AT trotmanlloydc competenceagainstinsufficiencywhyaremenmostlysafefromarareanddeadlyprostatecancer

Ejemplares similares